These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 30169827)

  • 1. Targeting kidney inflammation as a new therapy for primary hyperoxaluria?
    Martin-Higueras C; Ludwig-Portugall I; Hoppe B; Kurts C
    Nephrol Dial Transplant; 2019 Jun; 34(6):908-914. PubMed ID: 30169827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure.
    Hoppe B; Kemper MJ; Bökenkamp A; Portale AA; Cohn RA; Langman CB
    Kidney Int; 1999 Jul; 56(1):268-74. PubMed ID: 10411702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation and characterization of a novel rat model of primary hyperoxaluria type 1 with a nonsense mutation in alanine-glyoxylate aminotransferase gene.
    Li Y; Zheng R; Xu G; Huang Y; Li Y; Li D; Geng H
    Am J Physiol Renal Physiol; 2021 Mar; 320(3):F475-F484. PubMed ID: 33491567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I.
    Worcester EM; Evan AP; Coe FL; Lingeman JE; Krambeck A; Sommers A; Phillips CL; Milliner D
    Am J Physiol Renal Physiol; 2013 Dec; 305(11):F1574-84. PubMed ID: 24089413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy.
    Knauf F; Asplin JR; Granja I; Schmidt IM; Moeckel GW; David RJ; Flavell RA; Aronson PS
    Kidney Int; 2013 Nov; 84(5):895-901. PubMed ID: 23739234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1-mediated tissue injury.
    Anders HJ; Suarez-Alvarez B; Grigorescu M; Foresto-Neto O; Steiger S; Desai J; Marschner JA; Honarpisheh M; Shi C; Jordan J; Müller L; Burzlaff N; Bäuerle T; Mulay SR
    Kidney Int; 2018 Mar; 93(3):656-669. PubMed ID: 29241624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxalate, inflammasome, and progression of kidney disease.
    Ermer T; Eckardt KU; Aronson PS; Knauf F
    Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):363-71. PubMed ID: 27191349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.
    Chetyrkin SV; Kim D; Belmont JM; Scheinman JI; Hudson BG; Voziyan PA
    Kidney Int; 2005 Jan; 67(1):53-60. PubMed ID: 15610227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria.
    Lai C; Pursell N; Gierut J; Saxena U; Zhou W; Dills M; Diwanji R; Dutta C; Koser M; Nazef N; Storr R; Kim B; Martin-Higueras C; Salido E; Wang W; Abrams M; Dudek H; Brown BD
    Mol Ther; 2018 Aug; 26(8):1983-1995. PubMed ID: 29914758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria.
    Bollée G; Cochat P; Daudon M
    Can J Kidney Health Dis; 2015; 2():31. PubMed ID: 26380104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential for bilateral nephrectomy to reduce oxalate release after combined liver and kidney transplantation for primary hyperoxaluria type 1.
    Mizusawa Y; Parnham AP; Falk MC; Burke JR; Nicol D; Yamanaka J; Lynch SV; Strong RW
    Clin Transplant; 1997 Oct; 11(5 Pt 1):361-5. PubMed ID: 9361924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilateral native nephrectomy reduces systemic oxalate level after combined liver-kidney transplant: A case report.
    Villani V; Gupta N; Elias N; Vagefi PA; Markmann JF; Paul E; Traum AZ; Yeh H
    Pediatr Transplant; 2017 May; 21(3):. PubMed ID: 28261895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure.
    Zhao F; Bergstralh EJ; Mehta RA; Vaughan LE; Olson JB; Seide BM; Meek AM; Cogal AG; Lieske JC; Milliner DS;
    Clin J Am Soc Nephrol; 2016 Jan; 11(1):119-26. PubMed ID: 26656319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Primary hyperoxaluria: A review].
    Bouzidi H; Majdoub A; Daudon M; Najjar MF
    Nephrol Ther; 2016 Nov; 12(6):431-436. PubMed ID: 27372182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on primary hyperoxaluria.
    Hoppe B
    Nat Rev Nephrol; 2012 Jun; 8(8):467-75. PubMed ID: 22688746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Navigating the Evolving Landscape of Primary Hyperoxaluria: Traditional Management Defied by the Rise of Novel Molecular Drugs.
    Huang Y; Zhu W; Zhou J; Huang Q; Zeng G
    Biomolecules; 2024 Apr; 14(5):. PubMed ID: 38785918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1.
    Dutta C; Avitahl-Curtis N; Pursell N; Larsson Cohen M; Holmes B; Diwanji R; Zhou W; Apponi L; Koser M; Ying B; Chen D; Shui X; Saxena U; Cyr WA; Shah A; Nazef N; Wang W; Abrams M; Dudek H; Salido E; Brown BD; Lai C
    Mol Ther; 2016 Apr; 24(4):770-8. PubMed ID: 26758691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1.
    Hoppe B; Beck B; Gatter N; von Unruh G; Tischer A; Hesse A; Laube N; Kaul P; Sidhu H
    Kidney Int; 2006 Oct; 70(7):1305-11. PubMed ID: 16850020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary hyperoxaluria: clinical course, diagnosis, and treatment after kidney failure.
    Raju DL; Cantarovich M; Brisson ML; Tchervenkov J; Lipman ML
    Am J Kidney Dis; 2008 Jan; 51(1):e1-5. PubMed ID: 18155525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1.
    Kukreja A; Lasaro M; Cobaugh C; Forbes C; Tang JP; Gao X; Martin-Higueras C; Pey AL; Salido E; Sobolov S; Subramanian RR
    Nucleic Acid Ther; 2019 Apr; 29(2):104-113. PubMed ID: 30676254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.